

A detailed microscopic image of a tumor, showing a dense cluster of cells with a purple and blue hue, surrounded by a yellowish, porous-looking structure.

Humanity's most
challenging diseases...



Meet a radical new way
of conducting clinical trials

Cancer
meets its match



Omico.

Omico is changing the way we fight cancer by accelerating access to precision oncology

We are a national, independent, not-for-profit organisation, uniting Australia's world-class cancer institutes, researchers, industry partners and government like never before.

By leveraging a nationwide network of expertise and resources, we aim to **improve outcomes for all Australian cancer patients** through facilitating clinical trials and pioneering the use of genomic and molecular screening for prevention and treatment of cancer.

Our pioneering, collaborative model will also position **Australia globally as a premier hub for cancer research.**



We aim to improve outcomes for Australians with cancers, by



Accelerating the use of precision oncology

Use genomic profiling to detect unique genetic variations in cancer patients' tumours to **identify potential new targeted treatments options**



Growing clinical trials


Streamline biomarker-led clinical trials by **expediting patient recruitment and site setup, and attracting more international trials to Australia**



Modernising the Australian healthcare system

Advance a **research-led model of care** to open new treatment pathways for patients

Advance drug development and cancer research through the **collection of real-world data**



Adding value to all our partners

Industry: Reduce the cost and time needed for precision oncology clinical trials

Researchers: Greater innovation through genomic profiling and access to a national network of thought leaders to expand capabilities and knowledge base

Clinicians: Enhance your ability to make personalized treatment decisions by accessing comprehensive genomic profiling for your patients, providing valuable information to inform their care

Patients: Free genomic screening that may unlock new targeted treatment pathways for cancers

Government: Generate economic growth and attract more global investors in the Australian research sector, and improve patient outcomes

Advocacy Groups: Shared vision to ensure equitable opportunities for all patients to benefit from the latest advances in genomics and targeted treatments, to improve outcomes




How can we make
your biomarker-led
clinical trials **easier,**
faster and feasible?

Omico makes finding the *right* patients for your trials easier and faster

Traditional model


Currently industry bears the cost of conducting standard biomarker screening to identify patients with specific biomarkers per trial



Cost/test = \$500
\$10 million in screening costs to identify 200 patients*

Collaborative model

Omico uses comprehensive genomic profiling (CGP) to identify multiple biomarkers for **multiple trials at once**



Cost/test = \$2,500
\$10 million in screening costs to identify 400 patients*


Omico can help identify patients more efficiently through our national screening platform.

*Assumption: biomarker present in the population at a 1% frequency.

With Omico, increase clinical trial efficiency and reduce costs


Traditional model

Only local site patient catchment population available; limited/no institutional screening



Omico's Collaborative model

Strategically selected sites, accepting referred national patients



Open trials at fewer sites, faster

Leverage our national screening platform to identify and refer patients to your selected sites for recruitment

Improve clinical trial efficiency

PrOSPeCT is our landmark
precision oncology initiative



Precision Oncology Screening Platform Enabling Clinical Trials

Over 27 months, PrOSPeCT's Cancer Screening Program (CaSP) will provide free genomic profiling to **23,000 Australians with advanced or incurable cancers** and identify **potential matches for patients to clinical trials with new targeted therapies.**

This is the **largest cancer genomics initiative** in Australia.



prospect.

PrOSPeCT is anticipated to **drive growth** for the Australian research sector

PrOSPeCT is expected to:



ATTRACT
\$525M

New direct investment in locally based clinical trials



SAVE
\$135M

Savings from avoided health interventions (medicines, tests, hospitals)



CREATE
>650

Jobs created in genomics, clinical trials and diagnostics in two years

PrOSPeCT will position Australia as a premier hub for cancer research



Enabled by unique public-private funding and collaborative partnerships



Harnessing the combined expertise and resources of an established national network



Provide free CGP* to 23,000 patients with advanced or incurable cancers

CaSP
Cancer Screening Program



Advance drug development and cancer research with real-world data insights

*Comprehensive Genomic Profiling (CGP)

PrOSPeCT is enabled by public-private funding and partnerships



\$185M

public-private funding
and partnerships



PrOSPeCT Foundation Partners



Australian Government

(\$61.2M as part of the Modern
Manufacturing Strategy)



NSW
GOVERNMENT

(\$25M)



PrOSPeCT leverages expertise and resources across our national network

Our established collaborative network is continuously growing, further expanding Australia's research capabilities and capacity






Trials	Data Analytics
<ul style="list-style-type: none"> Global and local industry Small and large pharmaceutical companies Biotech Diagnostics Pathology services Health insurers Satellite industries CROs CMOs Workforce training and education 	<ul style="list-style-type: none"> Industry Data analytics companies Small and large biotech Pharmaceutical companies Government Regulatory Health Medical research












































































PrOSPeCT's CaSP provides free genomic profiling to 23,000 Australians with advanced or incurable cancers




PrOSPeCT will advance drug development and research with **real-world data insights**

Planned data integration to enhance analytic scope for richer healthcare insights

Collection of high quality real-world data through CaSP

Enhanced data insights shape future healthcare innovations, research and publications



Why partner with Omico?



Faster identification of eligible patients for your clinical trials

Accelerate patient recruitment through our national screening platform, saving you time and money



Optimise your clinical trial set up

Receive our guidance on strategic site selection for fewer sites and faster activation



Make your trials possible

Facilitate clinical trials that may have previously been impossible due to low patient numbers



Tap into our knowledge, expertise and experience

Draw on Omico's experience, data and network to support feasibility planning



Turn real-world data into real-time insights

Leverage our real-world database to inform future research and innovations

Together,

cancer meets its match

Learn more about
partnering with Omico.

Contact us at contact@omico.org.au

W: Omico.com.au **T:** 1800 954 350 **E:** contact@omico.org.au

© Copyright 2024. Australian Genomic Cancer Medicine Centre Ltd, trading as Omico, is a not-for-profit company limited by guarantee. Hilmer Building (E10), Union Rd, UNSW, Kensington, NSW, 2052.

Cancer
meets its match

